EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

NASDAQ:EKSO • US2826444000

10.05 USD
+0.03 (+0.3%)
Last: Feb 27, 2026, 03:37 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall EKSO gets a fundamental rating of 2 out of 10. We evaluated EKSO against 185 industry peers in the Health Care Equipment & Supplies industry. EKSO may be in some trouble as it scores bad on both profitability and health. EKSO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year EKSO has reported negative net income.
  • In the past year EKSO has reported a negative cash flow from operations.
  • EKSO had negative earnings in each of the past 5 years.
  • EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -49.21%, EKSO is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -110.14%, EKSO is doing worse than 63.24% of the companies in the same industry.
Industry RankSector Rank
ROA -49.21%
ROE -110.14%
ROIC N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • EKSO has a Gross Margin of 53.48%. This is comparable to the rest of the industry: EKSO outperforms 49.19% of its industry peers.
  • In the last couple of years the Gross Margin of EKSO has grown nicely.
  • EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for EKSO has been increased compared to 1 year ago.
  • Compared to 5 years ago, EKSO has more shares outstanding
  • The debt/assets ratio for EKSO has been reduced compared to a year ago.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • EKSO has an Altman-Z score of -15.61. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -15.61, EKSO is doing worse than 84.86% of the companies in the same industry.
  • A Debt/Equity ratio of 0.31 indicates that EKSO is not too dependend on debt financing.
  • EKSO has a Debt to Equity ratio of 0.31. This is comparable to the rest of the industry: EKSO outperforms 50.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -15.61
ROIC/WACCN/A
WACC9.58%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • EKSO has a Current Ratio of 1.66. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.66, EKSO is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.09 indicates that EKSO should not have too much problems paying its short term obligations.
  • EKSO has a worse Quick ratio (1.09) than 74.59% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.09
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.74%, which is quite impressive.
  • Looking at the last year, EKSO shows a very negative growth in Revenue. The Revenue has decreased by -16.59% in the last year.
  • Measured over the past years, EKSO shows a small growth in Revenue. The Revenue has been growing by 5.19% on average per year.
EPS 1Y (TTM)41.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%2.37%

3.2 Future

  • EKSO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.47% yearly.
  • EKSO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.94% yearly.
EPS Next Y74.41%
EPS Next 2Y39.68%
EPS Next 3Y25.84%
EPS Next 5Y16.47%
Revenue Next Year-17.71%
Revenue Next 2Y12.81%
Revenue Next 3Y10.94%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • EKSO's earnings are expected to grow with 25.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.68%
EPS Next 3Y25.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EKSO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (2/27/2026, 3:37:59 PM)

10.05

+0.03 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28
Earnings (Next)N/A
Inst Owners7.68%
Inst Owner Change2.49%
Ins Owners6.59%
Ins Owner Change0.42%
Market Cap34.07M
Revenue(TTM)14.75M
Net Income(TTM)-10.66M
Analysts80
Price Target9.69 (-3.58%)
Short Float %9.05%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.86%
Min EPS beat(2)9.95%
Max EPS beat(2)53.76%
EPS beat(4)2
Avg EPS beat(4)-3.7%
Min EPS beat(4)-71.57%
Max EPS beat(4)53.76%
EPS beat(8)4
Avg EPS beat(8)-15.61%
EPS beat(12)5
Avg EPS beat(12)-10.05%
EPS beat(16)8
Avg EPS beat(16)-7.85%
Revenue beat(2)0
Avg Revenue beat(2)-28.94%
Min Revenue beat(2)-53.24%
Max Revenue beat(2)-4.65%
Revenue beat(4)0
Avg Revenue beat(4)-21.89%
Min Revenue beat(4)-53.24%
Max Revenue beat(4)-1.24%
Revenue beat(8)0
Avg Revenue beat(8)-18.43%
Revenue beat(12)3
Avg Revenue beat(12)-9.03%
Revenue beat(16)4
Avg Revenue beat(16)-6.14%
PT rev (1m)0%
PT rev (3m)-72.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)54.03%
EPS NY rev (1m)0%
EPS NY rev (3m)51.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.31
P/FCF N/A
P/OCF N/A
P/B 3.52
P/tB 6.69
EV/EBITDA N/A
EPS(TTM)-5.68
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS4.35
BVpS2.86
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.21%
ROE -110.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.48%
FCFM N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score4
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.46%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.09
Altman-Z -15.61
F-Score4
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y74.41%
EPS Next 2Y39.68%
EPS Next 3Y25.84%
EPS Next 5Y16.47%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%2.37%
Revenue Next Year-17.71%
Revenue Next 2Y12.81%
Revenue Next 3Y10.94%
Revenue Next 5YN/A
EBIT growth 1Y6.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.95%
OCF growth 3YN/A
OCF growth 5YN/A

EKSO BIONICS HOLDINGS INC / EKSO FAQ

Can you provide the ChartMill fundamental rating for EKSO BIONICS HOLDINGS INC?

ChartMill assigns a fundamental rating of 2 / 10 to EKSO.


What is the valuation status for EKSO stock?

ChartMill assigns a valuation rating of 1 / 10 to EKSO BIONICS HOLDINGS INC (EKSO). This can be considered as Overvalued.


What is the profitability of EKSO stock?

EKSO BIONICS HOLDINGS INC (EKSO) has a profitability rating of 1 / 10.


Can you provide the financial health for EKSO stock?

The financial health rating of EKSO BIONICS HOLDINGS INC (EKSO) is 2 / 10.


Can you provide the expected EPS growth for EKSO stock?

The Earnings per Share (EPS) of EKSO BIONICS HOLDINGS INC (EKSO) is expected to grow by 74.41% in the next year.